A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome is a research paper published in Diagnostics (2022). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH/NCI
Grant: R01CA198887
NIH/NCI
Grant: R01CA241123
NIH/NCI
Grant: R01CA116161
NIH/NCI
Grant: R21CA263230
National Institutes of Health
Grant: 5R01CA241123-02
Advanced Computational Approaches to Delineating Dynamic Cancer Progression Processes by Using Massive Static Sample Data
National Institutes of Health
Grant: 5R01CA116161-07
Towards a non-invasive molecular test for bladder cancer
National Institutes of Health
Grant: 5R21CA263230-02
Humanized anti-CXCL1 antibody for bladder cancer therapeutics
National Institutes of Health
Grant: 3R01CA198887-02S2
MULTIPLEXED PROTEIN BIOMARKER-BASED ASSAY FOR THE DETECTION OF BLADDER CANCER
FWCI
0.84
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome